Form 4: Guardant Health Director Reports Stock Sale and Significant Equity Awards Under 10b5-1 Plan

Myrtle S. Potter, a Director at Guardant Health, Inc., reported the sale of a small number of common shares and the acquisition of substantial stock options and restricted stock units, all executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Myrtle S. Potter, a Director of Guardant Health, Inc. (GH), filed a Form 4 disclosing changes in her beneficial ownership.
• On June 18, 2025, Ms. Potter disposed of 26 shares of common stock at a price of $49.47 per share.
• Following this transaction, Ms. Potter beneficially owns 18,154 shares of common stock directly.
• On the same date, Ms. Potter acquired 6,833 stock options with an exercise price of $50.57 per share, expiring on June 18, 2035.
• Also on June 18, 2025, Ms. Potter acquired 4,203 Restricted Stock Units (RSUs).
• Both the stock options and RSUs are scheduled to vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next annual stockholders meeting, whichever is earlier.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a small sale of common stock, it was part of a pre-arranged 10b5-1 plan and is negligible compared to the significant acquisition of new stock options and Restricted Stock Units. The equity awards demonstrate continued alignment of the director's interests with the company's long-term performance.

Positives

• The acquisition of 6,833 stock options and 4,203 Restricted Stock Units (RSUs) indicates a significant increase in the director's equity exposure and alignment with shareholder interests.
• The vesting schedule for the options and RSUs, tied to the one-year anniversary of the grant or the next annual meeting, provides a clear timeline for future equity realization.

Negatives

• A disposition of 26 shares of common stock occurred, although this is a very small number relative to the director's total holdings and new equity awards.

Future Outlook

The acquired stock options and Restricted Stock Units are set to vest in full on the one-year anniversary of their grant date (June 18, 2025) or the date of the next annual stockholders meeting, whichever occurs earlier, indicating future equity realization for the director.

Industry Context

This Form 4 filing reflects routine insider trading activity, specifically a director's equity compensation and a minor pre-scheduled stock sale. Such filings are common across all publicly traded companies and do not inherently indicate broader industry trends, though they provide transparency into executive and director compensation practices within the healthcare technology sector.

Related Party Transactions

• Myrtle S. Potter, a Director of Guardant Health, Inc., engaged in transactions involving the company's common stock, stock options, and Restricted Stock Units. These are considered related party dealings as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a director's stock ownership changes and compensation, which can influence investor perception of management's alignment with shareholder interests. The acquisition of new equity awards generally signals confidence.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options and Restricted Stock Units are expected to vest in full on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Trading, Beneficial Ownership, Stock Options, Restricted Stock Units, RSUs, Rule 10b5-1 Plan, Director Compensation